Finch Therapeutics Group, Inc. (FNCH) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Finch Therapeutics Group, Inc. (FNCH) Bundle
Evaluate the financial outlook of Finch Therapeutics Group, Inc. (FNCH) with expert precision! This (FNCH) DCF Calculator provides pre-filled financial data while offering you the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your predictions.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 10.2 | 7.7 | 18.5 | .9 | .1 | .1 | .1 | .0 | .0 | .0 |
Revenue Growth, % | 0 | -23.98 | 140.08 | -95.35 | -87.57 | -26.73 | -26.73 | -26.73 | -26.73 | -26.73 |
EBITDA | -20.7 | -38.6 | -57.7 | -82.7 | -32.5 | -.1 | -.1 | .0 | .0 | .0 |
EBITDA, % | -203.47 | -500.66 | -311.27 | -9603.6 | -30357.01 | -100 | -100 | -100 | -100 | -100 |
Depreciation | .5 | .8 | 2.3 | 5.5 | 1.5 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 4.75 | 10.23 | 12.42 | 639.61 | 1420.56 | 45.48 | 45.48 | 45.48 | 45.48 | 45.48 |
EBIT | -21.1 | -39.4 | -60.0 | -88.2 | -34.0 | -.1 | -.1 | .0 | .0 | .0 |
EBIT, % | -208.21 | -510.9 | -323.68 | -10243.21 | -31777.57 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 42.2 | 99.7 | 133.5 | 71.0 | 25.1 | .1 | .1 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 4.7 | 1.1 | .5 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 46.74 | 14.19 | 2.67 | 16.72 | 0 | 16.06 | 16.06 | 16.06 | 16.06 | 16.06 |
Inventories | .0 | .0 | -9.1 | -3.5 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 0.000009848336 | 0 | -48.94 | -408.01 | 0 | -29.79 | -29.79 | -29.79 | -29.79 | -29.79 |
Accounts Payable | .7 | 2.6 | 3.7 | 1.1 | .1 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 6.45 | 33.96 | 20.17 | 127.41 | 131.78 | 52.11 | 52.11 | 52.11 | 52.11 | 52.11 |
Capital Expenditure | -1.0 | -2.6 | -16.0 | -2.2 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | -9.9 | -34.11 | -86.25 | -253.43 | 0 | -46.05 | -46.05 | -46.05 | -46.05 | -46.05 |
Tax Rate, % | 4.42 | 4.42 | 4.42 | 4.42 | 4.42 | 4.42 | 4.42 | 4.42 | 4.42 | 4.42 |
EBITAT | -20.8 | -39.3 | -57.6 | -87.5 | -32.5 | -.1 | -.1 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -25.4 | -35.6 | -60.5 | -92.0 | -35.3 | -.2 | -.1 | -.1 | .0 | .0 |
WACC, % | 6.71 | 6.75 | 6.65 | 6.74 | 6.64 | 6.7 | 6.7 | 6.7 | 6.7 | 6.7 |
PV UFCF | ||||||||||
SUM PV UFCF | -.3 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | -1 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | 5 | |||||||||
Equity Value | -6 | |||||||||
Diluted Shares Outstanding, MM | 2 | |||||||||
Equity Value Per Share | -3.58 |
What You Will Get
- Real Finch Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Finch Therapeutics' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Access accurate pre-loaded historical data and future projections specific to Finch Therapeutics Group, Inc. (FNCH).
- Tailored Forecast Assumptions: Modify yellow-highlighted cells such as WACC, growth rates, and profit margins to fit your analysis.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
- Interactive Dashboard: User-friendly charts and summaries to effectively visualize your valuation outcomes.
- Designed for All Users: A straightforward, intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the ready-to-use Excel file featuring Finch Therapeutics Group, Inc. (FNCH) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to suit your analysis.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Leverage the valuation insights to inform your investment choices.
Why Choose This Calculator?
- Designed for Experts: A specialized tool utilized by researchers, financial analysts, and biopharma consultants.
- Comprehensive Data: Finch Therapeutics' historical and projected financials preloaded for precise analysis.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Transparent Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth calculation process.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing Finch Therapeutics Group, Inc. (FNCH) investments.
- Biotech Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Finch Therapeutics Group, Inc. (FNCH).
- Students and Educators: Utilize real-time data to practice and teach financial modeling in the biotech sector.
- Life Sciences Enthusiasts: Gain insights into how biotech companies like Finch Therapeutics Group, Inc. (FNCH) are valued in the market.
What the Template Contains
- Historical Data: Includes Finch Therapeutics Group’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Finch Therapeutics Group’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Finch Therapeutics Group’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.